US 10,292,943 B2Granted

Delivery of bioactive, nanoencapsulated antioxidants

AssigneeBoard of Supervisors of Louisiana State University and Agricultural and Mechanical College

InventorsCristina M. Sabliov, Carlos E. Astete, Ede Bodoki, Oliviu Vostinaru, Ovidiu Ciprian Samoil{hacek over (a)}, Elena Dinte

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Claims12

Dependent claims

A method for delivering lutein to the eye of a mammal, wherein the mammal has one or more cataracts;

said method comprising topically administering to the mammal's eye a composition that comprises a mixture of nanoparticles and a hydrogel:
(a) wherein the nanoparticles comprise:
(i) a synthetic polymer or a protein, (ii) lutein, and (iii) a surfactant;
wherein the polymer or protein entraps the lutein;
wherein the surfactant associates with the polymer or protein;
wherein the nanoparticles have a diameter between 50 nm and 250 nm;
wherein the nanoparticles are more hydrophilic than is native lutein;
wherein the lutein in the nanoparticles has greater resistance to degradation by oxygen, to degradation by ultraviolet light, or both than does free lutein;
(b) wherein the hydrogel comprises a mixture of water, a thermoreversible gel-forming polymer, and a bioadhesive polymer;
wherein the composition is liquid at 25° C.;
wherein the thermoreversible gel-forming polymer causes the composition to become a gel at the temperature of the conjunctival sac or of the surface of the cornea of the mammal;
and wherein the bioadhesive polymer causes the gel to adhere to the conjunctival mucosa and cornea more strongly than the gel would adhere without the bioadhesive polymer;
(c) wherein the composition is applied as a liquid to the surface of the cornea or into the conjunctival sac;
wherein the temperature of the conjunctival sac or of the surface of the cornea causes the composition to form a gel;
wherein the gel adheres to the conjunctival mucosa, to the surface of the cornea, or both;
and wherein the adhering gel releases lutein to the eye over a period of time;
and
(d) wherein the mammal has one or more cataracts, and said method alleviates the symptoms of one or more cataracts.

15 more elements

A method for delivering lutein to the eye of a mammal, wherein the mammal is at risk for developing cataracts;

said method comprising topically administering to the mammal's eye a composition that comprises a mixture of nanoparticles and a hydrogel:
(a) wherein the nanoparticles comprise:
(i) a synthetic polymer or a protein, (ii) lutein, and (iii) a surfactant;
wherein the polymer or protein entraps the lutein;
wherein the surfactant associates with the polymer or protein;
wherein the nanoparticles have a diameter between 50 nm and 250 nm;
wherein the nanoparticles are more hydrophilic than is native lutein;
wherein the lutein in the nanoparticles has greater resistance to degradation by oxygen, to degradation by ultraviolet light, or both than does free lutein;
(b) wherein the hydrogel comprises a mixture of water, a thermoreversible gel-forming polymer, and a bioadhesive polymer;
wherein the composition is liquid at 25° C.;
wherein the thermoreversible gel-forming polymer causes the composition to become a gel at the temperature of the conjunctival sac or of the surface of the cornea of the mammal;
and wherein the bioadhesive polymer causes the gel to adhere to the conjunctival mucosa and cornea more strongly than the gel would adhere without the bioadhesive polymer;
(c) wherein the composition is applied as a liquid to the surface of the cornea or into the conjunctival sac;
wherein the temperature of the conjunctival sac or of the surface of the cornea causes the composition to form a gel;
wherein the gel adheres to the conjunctival mucosa, to the surface of the cornea, or both;
and wherein the adhering gel releases lutein to the eye over a period of time;
and
(d) wherein the mammal is at risk for developing cataracts.

15 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/502,415Filed 10 Aug 2015 · us provisional application
Priority: 11 Aug 2014
Published: US 2017/0216221 A13 Aug 2017
Granted: 21 May 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/047
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates: having two or more hydroxy groups, e.g. sorbitol
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/06
Medicinal preparations characterised by special physical form: ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
A61K 9/5146
Organic macromolecular compounds; Dendrimers: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g.…